Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Influenza

Free Subscription Articles published in J Virol Retrieve available abstracts of 276 articles: HTML format

Single Articles

July 2025
1. KANDEL S, Babujee L, Guan L, Dahn R, et al
   Phylogenetic analysis of H5N1 influenza viruses isolated from dairy cattle in Texas in December 2024.
   J Virol. 2025 Jul 8:e0058025. doi: 10.1128/jvi.00580.
   PubMed    
   
   
   June 2025
2. CHEN PR, White SN, Walker LR, Kapczynski DR, et al
   Genetic resilience or resistance in poultry against avian influenza virus: mirage or reality?
   J Virol. 2025 Jun 30:e0082025. doi: 10.1128/jvi.00820.
   PubMed     Abstract available
   
   
   
3. ESPARZA M, El Zahed SS, Karakus U, Niederstrasser H, et al
   Contrasting interferon-mediated antiviral responses in human lung adenocarcinoma cells.
   J Virol. 2025;99:e0046925.
   PubMed     Abstract available
   
   
   
4. SONG Q, Yang H, Zhu H, Hu Y, et al
   Hydrophobic residue substitutions enhance the stability and in vivo immunogenicity of respiratory syncytial virus fusion protein.
   J Virol. 2025;99:e0008725.
   PubMed     Abstract available
   
   
   
5. JONES JE, Lakdawala SS
   Host origin is a determinant of coevolution between gene segments of avian H9 influenza viruses.
   J Virol. 2025 Jun 13:e0151824. doi: 10.1128/jvi.01518.
   PubMed     Abstract available
   
   
   
6. LV H, Teo QW, Lee C-CD, Liang W, et al
   Correction for Lv et al., "Differential antigenic imprinting effects between influenza H1N1 hemagglutinin and neuraminidase in a mouse model".
   J Virol. 2025 Jun 12:e0078325. doi: 10.1128/jvi.00783.
   PubMed    
   
   
   
7. SULLIVAN OM, Nesbitt DJ, Schaack GA, Feltman EM, et al
   IFIT3 RNA-binding activity promotes influenza A virus infection and translation efficiency.
   J Virol. 2025 Jun 11:e0028625. doi: 10.1128/jvi.00286.
   PubMed     Abstract available
   
   
   
8. COGGON A, Lopes S, Simon G, Arendsee Z, et al
   Quantifying the zoonotic risk profile of European influenza A viruses in swine from 2010 to 2020 inclusive.
   J Virol. 2025 Jun 4:e0030625. doi: 10.1128/jvi.00306.
   PubMed     Abstract available
   
   
   
9. ROBINSON-MCCARTHY LR, Zirckel KE, Simmons HC, Le Sage V, et al
   A replicating recombinant vesicular stomatitis virus model for dairy cattle H5N1 influenza virus glycoprotein evolution.
   J Virol. 2025 Jun 4:e0038925. doi: 10.1128/jvi.00389.
   PubMed     Abstract available
   
   
   
10. SEIBERT B, Caceres CJ, Gay LC, Shetty N, et al
    Air-liquid interface model for influenza aerosol exposure in vitro.
    J Virol. 2025 Jun 3:e0061925. doi: 10.1128/jvi.00619.
    PubMed     Abstract available
    
    
    May 2025
11. ZHANG Q, Zhang L, Li J, Zhang W, et al
    hnRNPM regulates influenza A virus replication through distinct mechanisms in human and avian cells: implications for cross-species transmission.
    J Virol. 2025 May 28:e0006725. doi: 10.1128/jvi.00067.
    PubMed     Abstract available
    
    
    
12. BEAN DJ, Liang YM, Avila F, He X, et al
    Endemic coronavirus infection is associated with SARS-CoV-2 Fc receptor-binding antibodies.
    J Virol. 2025 May 19:e0055025. doi: 10.1128/jvi.00550.
    PubMed     Abstract available
    
    
    
13. KOUTSAKOS M, Reynaldi A, Aban M, Barr IG, et al
    Binding antibody titers against the hemagglutinin and neuraminidase correlate with protection against medically attended influenza A and B disease.
    J Virol. 2025 May 13:e0039125. doi: 10.1128/jvi.00391.
    PubMed     Abstract available
    
    
    
14. FURUSAWA Y, Iwatsuki-Horimoto K, Yamayoshi S, Kawaoka Y, et al
    The NSP6-L260F substitution in SARS-CoV-2 BQ.1.1 and XBB.1.16 lineages compensates for the reduced viral polymerase activity caused by mutations in NSP13 and NSP14.
    J Virol. 2025 May 13:e0065625. doi: 10.1128/jvi.00656.
    PubMed     Abstract available
    
    
    
15. KONDO T, Suzuki R, Yajima H, Kawahara S, et al
    Determinants of susceptibility to SARS-CoV-2 infection in murine ACE2.
    J Virol. 2025 May 12:e0054325. doi: 10.1128/jvi.00543.
    PubMed     Abstract available
    
    
    
16. XIE Z, Yang J, Jiao W, Li X, et al
    Clade 2.3.4.4b highly pathogenic avian influenza H5N1 viruses: knowns, unknowns, and challenges.
    J Virol. 2025 May 9:e0042425. doi: 10.1128/jvi.00424.
    PubMed     Abstract available
    
    
    
17. LI Y, Quan X, Chen R, Wang X, et al
    Adaptive selection of quasispecies during in vivo passaging in chickens, mice, and ferrets results in host-specific strains for the H9N2 avian influenza virus.
    J Virol. 2025 May 8:e0015125. doi: 10.1128/jvi.00151.
    PubMed     Abstract available
    
    
    
18. LUGANO D, Mwangi K, Mware B, Kibet G, et al
    Characterization of SARS-CoV-2 intrahost genetic evolution in vaccinated and non-vaccinated patients from the Kenyan population.
    J Virol. 2025 May 6:e0048225. doi: 10.1128/jvi.00482.
    PubMed     Abstract available
    
    
    April 2025
19. ZHANG S, Xu C-L, Wang J, Xiong X, et al
    Spike proteins of coronaviruses activate mast cells for degranulation via stimulating Src/PI3K/AKT/Ca(2+) intracellular signaling cascade.
    J Virol. 2025 Apr 30:e0007825. doi: 10.1128/jvi.00078.
    PubMed     Abstract available
    
    
    
20. NEGI V, Kuhn RJ
    A BSL-2 chimeric system designed to screen SARS-CoV-2 E protein ion channel inhibitors.
    J Virol. 2025 Apr 30:e0225224. doi: 10.1128/jvi.02252.
    PubMed     Abstract available
    
    
    
21. SUN H, Yang Q, Zhang Y, Cui S, et al
    Syntaxin-6 restricts SARS-CoV-2 infection by facilitating virus trafficking to autophagosomes.
    J Virol. 2025 Apr 25:e0000225. doi: 10.1128/jvi.00002.
    PubMed     Abstract available
    
    
    
22. DE AVILA AI, Soria ME, Martinez-Gonzalez B, Somovilla P, et al
    SARS-CoV-2 biological clones are genetically heterogeneous and include clade-discordant residues.
    J Virol. 2025 Apr 24:e0225024. doi: 10.1128/jvi.02250.
    PubMed     Abstract available
    
    
    
23. LE CTT, Kim K-H, Raha JR, Bhatnagar N, et al
    Dual roles of influenza B virus neuraminidase mRNA vaccine in enhancing cross-lineage protection by supplementing inactivated split vaccination.
    J Virol. 2025 Apr 23:e0229424. doi: 10.1128/jvi.02294.
    PubMed     Abstract available
    
    
    
24. LOWEN AC, Baker AL, Bowman AS, Garcia-Sastre A, et al
    Pandemic risk stemming from the bovine H5N1 outbreak: an account of the knowns and unknowns.
    J Virol. 2025;99:e0005225.
    PubMed     Abstract available
    
    
    
25. KAWAKITA T, Sekiya T, Kameda Y, Nomura N, et al
    ARNAX is an ideal adjuvant for COVID-19 vaccines to enhance antigen-specific CD4(+) and CD8(+) T-cell responses and neutralizing antibody induction.
    J Virol. 2025 Apr 15:e0229024. doi: 10.1128/jvi.02290.
    PubMed     Abstract available
    
    
    
26. ADU OF, Sempere Borau M, Fruh SP, Karakus U, et al
    Cell binding, uptake, and infection of influenza A virus using recombinant antibody-based receptors.
    J Virol. 2025 Apr 10:e0227524. doi: 10.1128/jvi.02275.
    PubMed     Abstract available
    
    
    
27. ZHOU B, Gui Q, Liu C, Guo H, et al
    Structure and function of an unusual R452-dependent monoclonal antibody against SARS-CoV-2.
    J Virol. 2025 Apr 8:e0184424. doi: 10.1128/jvi.01844.
    PubMed     Abstract available
    
    
    
28. XU S, Liu Y, Luo C, Zhou M, et al
    Identification and characterization of a broadly neutralizing and protective nanobody against the HA1 domain of H5 avian influenza virus hemagglutinin.
    J Virol. 2025 Apr 7:e0209024. doi: 10.1128/jvi.02090.
    PubMed     Abstract available
    
    
    
29. XIAO X, Wang X, Xu F, Liang Y, et al
    Synergistic effects of PA (S184N) and PB2 (E627K) mutations on the increased pathogenicity of H3N2 canine influenza virus infections in mice and dogs.
    J Virol. 2025 Apr 4:e0198424. doi: 10.1128/jvi.01984.
    PubMed     Abstract available
    
    
    
30. XIAO X, Li S, Zheng Z, Ji Y, et al
    Targeting USP22 to promote K63-linked ubiquitination and degradation of SARS-CoV-2 nucleocapsid protein.
    J Virol. 2025 Apr 4:e0223424. doi: 10.1128/jvi.02234.
    PubMed     Abstract available
    
    
    March 2025
31. GHIMIRE R, Shrestha R, Amaradhi R, Liu L, et al
    Toll-like receptor 7 (TLR7)-mediated antiviral response protects mice from lethal SARS-CoV-2 infection.
    J Virol. 2025 Mar 31:e0166824. doi: 10.1128/jvi.01668.
    PubMed     Abstract available
    
    
    
32. NOETTGER S, Zech F, Nchioua R, Pastorio C, et al
    Role of N-linked glycosylation sites in human ACE2 in SARS-CoV-2 and hCoV-NL63 infection.
    J Virol. 2025 Mar 28:e0220224. doi: 10.1128/jvi.02202.
    PubMed     Abstract available
    
    
    
33. KRAMMER F, Hermann E, Rasmussen AL
    Highly pathogenic avian influenza H5N1: history, current situation, and outlook.
    J Virol. 2025 Mar 27:e0220924. doi: 10.1128/jvi.02209.
    PubMed     Abstract available
    
    
    
34. YU L, Jiang Y, Rang H, Wang X, et al
    Restriction of influenza A virus replication by host DCAF7-CRL4B axis.
    J Virol. 2025 Mar 27:e0013325. doi: 10.1128/jvi.00133.
    PubMed     Abstract available
    
    
    
35. JANA ID, Kanjo K, Roy S, Bhasin M, et al
    Early 2022 breakthrough infection sera from India target the conserved cryptic class 5 epitope to counteract immune escape by SARS-CoV-2 variants.
    J Virol. 2025 Mar 26:e0005125. doi: 10.1128/jvi.00051.
    PubMed     Abstract available
    
    
    
36. LI P, Faraone JN, Hsu CC, Chamblee M, et al
    Role of glycosylation mutations at the N-terminal domain of SARS-CoV-2 XEC variant in immune evasion, cell-cell fusion, and spike stability.
    J Virol. 2025 Mar 26:e0024225. doi: 10.1128/jvi.00242.
    PubMed     Abstract available
    
    
    
37. LANG Y, Shi L, Roy S, Gupta D, et al
    Detection of antibodies against influenza A viruses in cattle.
    J Virol. 2025 Mar 25:e0213824. doi: 10.1128/jvi.02138.
    PubMed     Abstract available
    
    
    
38. JOHN K, Huntress I, Smith E, Chou H, et al
    Human long noncoding RNA VILMIR is induced by major respiratory viral infections and modulates the host interferon response.
    J Virol. 2025 Mar 25:e0014125. doi: 10.1128/jvi.00141.
    PubMed     Abstract available
    
    
    
39. DADONAITE B, Burrell AR, Logue J, Chu HY, et al
    SARS-CoV-2 neutralizing antibody specificities differ dramatically between recently infected infants and immune-imprinted individuals.
    J Virol. 2025 Mar 25:e0010925. doi: 10.1128/jvi.00109.
    PubMed     Abstract available
    
    
    
40. BEAVIS AC, Xiao P, Gingerich MC, Briggs K, et al
    A parainfluenza virus 5 (PIV5)-vectored intranasal SARS-CoV-2 vaccine (CVXGA1) elicits protective and long-lasting immunity in nonhuman primates.
    J Virol. 2025 Mar 21:e0199024. doi: 10.1128/jvi.01990.
    PubMed     Abstract available
    
    
    
41. BEAVIS AC, Li Z, Briggs K, Gingerich MC, et al
    Efficacy of parainfluenza virus 5 (PIV5)-vectored intranasal COVID-19 vaccine as a single dose primer and booster against SARS-CoV-2 variants.
    J Virol. 2025 Mar 21:e0198924. doi: 10.1128/jvi.01989.
    PubMed     Abstract available
    
    
    
42. SIMS A, Weir DJ, Cole SJ, Hutchinson E, et al
    SARS-CoV-2 cellular coinfection is limited by superinfection exclusion.
    J Virol. 2025 Mar 21:e0207724. doi: 10.1128/jvi.02077.
    PubMed     Abstract available
    
    
    
43. HU H, Zhang Y, Zheng H, Zhao X, et al
    Thymic stromal lymphopoietin improves protective immunity of the SARS-CoV-2 subunit vaccine by inducing dendritic cell-dependent germinal center response.
    J Virol. 2025 Mar 4:e0232324. doi: 10.1128/jvi.02323.
    PubMed     Abstract available
    
    
    
44. KARL V, Hofmann M, Thimme R
    Role of antiviral CD8+ T cell immunity to SARS-CoV-2 infection and vaccination.
    J Virol. 2025 Mar 3:e0135024. doi: 10.1128/jvi.01350.
    PubMed     Abstract available
    
    
    February 2025
45. QU X, Zhu Z, Zhou X, Wu X, et al
    KRT9 is required for GBP5 suppression of human respiratory syncytial virus.
    J Virol. 2025;99:e0202924.
    PubMed     Abstract available
    
    
    
46. MILLER JL, Leedale C, Kang D, Lilue J, et al
    Prostaglandin D2 delays CD8+ T-cell responses and respiratory syncytial virus clearance in geriatric cotton rats.
    J Virol. 2025;99:e0186324.
    PubMed     Abstract available
    
    
    
47. HAO T, Xie Y, Chai Y, Zhang W, et al
    Structural basis of receptor-binding adaptation of human-infecting H3N8 influenza A virus.
    J Virol. 2025 Feb 24:e0106524. doi: 10.1128/jvi.01065.
    PubMed     Abstract available
    
    
    
48. KOBAYASHI D, Hiono T, Arakawa H, Kaji H, et al
    Deglycosylation and truncation in the neuraminidase stalk are functionally equivalent in enhancing the pathogenicity of a high pathogenicity avian influenza virus in chickens.
    J Virol. 2025 Feb 14:e0147824. doi: 10.1128/jvi.01478.
    PubMed     Abstract available
    
    
    
49. MA R, Zhang X, Li R, Dong X, et al
    PLSCR1 suppresses SARS-CoV-2 infection by downregulating cell surface ACE2.
    J Virol. 2025 Feb 13:e0208524. doi: 10.1128/jvi.02085.
    PubMed     Abstract available
    
    
    
50. FURUSAWA Y, Kiso M, Uraki R, Sakai-Tagawa Y, et al
    Amino acid substitutions in NSP6 and NSP13 of SARS-CoV-2 contribute to superior virus growth at low temperatures.
    J Virol. 2025 Feb 12:e0221724. doi: 10.1128/jvi.02217.
    PubMed     Abstract available
    
    
    
51. KUHN AJ, Outlaw VK, Marcink TC, Yu Z, et al
    Enhancing the solubility of SARS-CoV-2 inhibitors to increase future prospects for clinical development.
    J Virol. 2025 Feb 4:e0215924. doi: 10.1128/jvi.02159.
    PubMed     Abstract available
    
    
    
52. PHAN T, Ribeiro RM, Edelstein GE, Boucau J, et al
    Modeling suggests SARS-CoV-2 rebound after nirmatrelvir-ritonavir treatment is driven by target cell preservation coupled with incomplete viral clearance.
    J Virol. 2025 Feb 4:e0162324. doi: 10.1128/jvi.01623.
    PubMed     Abstract available
    
    
    
53. WANG X, Dong M, Wu X, Schnepf D, et al
    Single-cell transcriptomics reveals a compartmentalized antiviral interferon response in the nasal epithelium of mice.
    J Virol. 2025 Feb 4:e0141324. doi: 10.1128/jvi.01413.
    PubMed     Abstract available
    
    
    
54. PARK H, Kingstad-Bakke B, Cleven T, Jung M, et al
    Diversifying T-cell responses: safeguarding against pandemic influenza with mosaic nucleoprotein.
    J Virol. 2025 Feb 3:e0086724. doi: 10.1128/jvi.00867.
    PubMed     Abstract available
    
    
    January 2025
55. KIRKPATRICK ROUBIDOUX E, Meliopoulos V, Livingston B, Brigleb PH, et al
    Intraductal infection with H5N1 clade 2.3.4.4b influenza virus.
    J Virol. 2025 Jan 31:e0192724. doi: 10.1128/jvi.01927.
    PubMed    
    
    
    
56. ZHAO B, Sun Z, Wang S, Shi Z, et al
    Structural basis of different neutralization capabilities of monoclonal antibodies against H7N9 virus.
    J Virol. 2025;99:e0140024.
    PubMed     Abstract available
    
    
    
57. SAMAAN P, Korosec CS, Budylowski P, Chau SLL, et al
    mRNA vaccine-induced SARS-CoV-2 spike-specific IFN-gamma and IL-2 T-cell responses are predictive of serological neutralization and are transiently enhanced by pre-existing cross-reactive immunity.
    J Virol. 2025 Jan 31:e0168524. doi: 10.1128/jvi.01685.
    PubMed     Abstract available
    
    
    
58. LYTRAS S, Lamb KD, Ito J, Grove J, et al
    Pathogen genomic surveillance and the AI revolution.
    J Virol. 2025 Jan 29:e0160124. doi: 10.1128/jvi.01601.
    PubMed     Abstract available
    
    
    
59. WANG Y, Xia B, Gao Z
    A comprehensive review of current insights into the virulence factors of SARS-CoV-2.
    J Virol. 2025 Jan 29:e0204924. doi: 10.1128/jvi.02049.
    PubMed     Abstract available
    
    
    
60. SADLER HL, Rijal P, Tan TK, Townsend ARM, et al
    A locally administered single-cycle influenza vaccine expressing a non-fusogenic stabilized hemagglutinin stimulates strong T-cell and neutralizing antibody immunity.
    J Virol. 2025 Jan 27:e0033124. doi: 10.1128/jvi.00331.
    PubMed     Abstract available
    
    
    
61. FOO IJH, Chua BY, Chang SY, Jia X, et al
    Prior influenza virus infection alleviates an arbovirus encephalitis by reducing viral titer, inflammation, and cellular infiltrates in the central nervous system.
    J Virol. 2025 Jan 16:e0210824. doi: 10.1128/jvi.02108.
    PubMed     Abstract available
    
    
    
62. NAGHIBOSADAT M, Babuadze GG, Pei Y, Hurst J, et al
    Vaccination against SARS-CoV-2 provides low-level cross-protection against common cold coronaviruses in mouse and non-human primate animal models.
    J Virol. 2025 Jan 16:e0139024. doi: 10.1128/jvi.01390.
    PubMed     Abstract available
    
    
    
63. CAI C, Pham TNQ, Adam D, Brochiero E, et al
    Sensing of SARS-CoV-2-infected cells by plasmacytoid dendritic cells is modulated via an interplay between CD54/ICAM-1 and CD11a/LFA-1 alpha(L) integrin.
    J Virol. 2025 Jan 13:e0123524. doi: 10.1128/jvi.01235.
    PubMed     Abstract available
    
    
    
64. PERRY SS, Brice DC, Sakr AA, Kandeil A, et al
    Modulation of cytokeratin and cytokine/chemokine expression following influenza virus infection of differentiated human tonsillar epithelial cells.
    J Virol. 2025 Jan 10:e0146024. doi: 10.1128/jvi.01460.
    PubMed     Abstract available
    
    
    
65. FOX CR, Yousef NN, Varudkar N, Shiffer EM, et al
    Resistance to complement-mediated lysis of parainfluenza virus 5-infected cells is acquired after transition from acute to persistent infection.
    J Virol. 2025 Jan 10:e0189524. doi: 10.1128/jvi.01895.
    PubMed     Abstract available
    
    
    
66. ARORA P, Zhang L, Nehlmeier I, Kempf A, et al
    Host cell lectins ASGR1 and DC-SIGN jointly with TMEM106B confer ACE2 independence and imdevimab resistance to SARS-CoV-2 pseudovirus with spike mutation E484D.
    J Virol. 2025 Jan 10:e0123024. doi: 10.1128/jvi.01230.
    PubMed     Abstract available
    
    
    
67. HU H, Leng C, Shu Y, Peng L, et al
    Structural insights into hybridoma-derived neutralizing monoclonal antibodies against Omicron BA.5 and XBB.1.16 variants of SARS-CoV-2.
    J Virol. 2025 Jan 7:e0130724. doi: 10.1128/jvi.01307.
    PubMed     Abstract available
    
    
    
68. GUNAWARDENE CD, Wong L-YR
    Betacoronavirus internal protein: role in immune evasion and viral pathogenesis.
    J Virol. 2025 Jan 6:e0135324. doi: 10.1128/jvi.01353.
    PubMed     Abstract available
    
    
    December 2024
69. CAI Z, Ni W, Li W, Wu Z, et al
    SARS-CoV-2 S protein disrupts the formation of ISGF3 complex through conserved S2 subunit to antagonize type I interferon response.
    J Virol. 2024 Dec 19:e0151624. doi: 10.1128/jvi.01516.
    PubMed     Abstract available
    
    
    
70. XIONG Y, Tao K, Li T, Zhou Y, et al
    Both chebulagic acid and punicalagin inhibit respiratory syncytial virus entry via multi-targeting glycoprotein and fusion protein.
    J Virol. 2024;98:e0153624.
    PubMed     Abstract available
    
    
    
71. NEAL HE, Barrett CT, Edmonds K, Moncman CL, et al
    Examination of respiratory syncytial virus fusion protein proteolytic processing and roles of the P27 domain.
    J Virol. 2024;98:e0163924.
    PubMed     Abstract available
    
    
    
72. TAKAHASHI T, Amarbayasgalan S, Ueno S, Sugiura Y, et al
    Lethal model for respiratory syncytial virus infection using C57BL/6 mice.
    J Virol. 2024;98:e0177224.
    PubMed     Abstract available
    
    
    
73. LV H, Teo QW, Lee C-CD, Liang W, et al
    Differential antigenic imprinting effects between influenza H1N1 hemagglutinin and neuraminidase in a mouse model.
    J Virol. 2024 Dec 5:e0169524. doi: 10.1128/jvi.01695.
    PubMed     Abstract available
    
    
    
74. YANG K, Nizami S, Hu S, Zou L, et al
    Genetic diversity of highly pathogenic avian influenza H5N6 and H5N8 viruses in poultry markets in Guangdong, China, 2020-2022.
    J Virol. 2024 Dec 4:e0114524. doi: 10.1128/jvi.01145.
    PubMed     Abstract available
    
    
    November 2024
75. KAKIZAKI M, Hashimoto R, Nagata N, Yamamoto T, et al
    The respective roles of TMPRSS2 and cathepsins for SARS-CoV-2 infection in human respiratory organoids.
    J Virol. 2024 Nov 27:e0185324. doi: 10.1128/jvi.01853.
    PubMed     Abstract available
    
    
    
76. SHETTY N, Shephard MJ, Rockey NC, Macenczak H, et al
    Influenza virus infection and aerosol shedding kinetics in a controlled human infection model.
    J Virol. 2024 Nov 26:e0161224. doi: 10.1128/jvi.01612.
    PubMed     Abstract available
    
    
    
77. FUJIMOTO Y, Ozaki K, Ono E
    Chicken ANP32A-independent replication of highly pathogenic avian influenza viruses potentially leads to mammalian adaptation-related amino acid substitutions in viral PB2 and PA proteins.
    J Virol. 2024 Nov 21:e0184024. doi: 10.1128/jvi.01840.
    PubMed     Abstract available
    
    
    
78. BOLLAND W, Marechal I, Petiot C, Porrot F, et al
    SARS-CoV-2 entry and fusion are independent of ACE2 localization to lipid rafts.
    J Virol. 2024 Nov 21:e0182324. doi: 10.1128/jvi.01823.
    PubMed     Abstract available
    
    
    
79. PATINO-GALINDO J, Garcia-Sastre A, Kuhn JH, Rabadan R, et al
    Recombination across distant coronavirid species and genera is a rare event with distinct genomic features.
    J Virol. 2024 Nov 19:e0110024. doi: 10.1128/jvi.01100.
    PubMed     Abstract available
    
    
    
80. LI C, Culhane MR, Schroeder DC, Cheeran MC-J, et al
    Quantifying the impact of vaccination on transmission and diversity of influenza A variants in pigs.
    J Virol. 2024 Nov 12:e0124524. doi: 10.1128/jvi.01245.
    PubMed     Abstract available
    
    
    
81. POWELL JD, Thomas MN, Anderson TK, Zeller MA, et al
    2018-2019 human seasonal H3N2 influenza A virus spillovers into swine with demonstrated virus transmission in pigs were not sustained in the pig population.
    J Virol. 2024 Nov 11:e0008724. doi: 10.1128/jvi.00087.
    PubMed     Abstract available
    
    
    
82. CHEN D, Zhang W, Xiao B, Xu B, et al
    Effect of wild-type vaccine doses on BA.5 hybrid immunity, disease severity, and XBB reinfection risk.
    J Virol. 2024 Nov 5:e0128524. doi: 10.1128/jvi.01285.
    PubMed     Abstract available
    
    
    
83. SUN X, Belser JA, Pulit-Penaloza JA, Brock N, et al
    Dissecting the role of the HA1-226 leucine residue in the fitness and airborne transmission of an A(H9N2) avian influenza virus.
    J Virol. 2024 Nov 4:e0092824. doi: 10.1128/jvi.00928.
    PubMed     Abstract available
    
    
    
84. STEIN SC, Hansen G, Ssebyatika G, Stroh LJ, et al
    A human monoclonal antibody neutralizing SARS-CoV-2 Omicron variants containing the L452R mutation.
    J Virol. 2024 Nov 4:e0122324. doi: 10.1128/jvi.01223.
    PubMed     Abstract available
    
    
    
85. PARRY RH, Lytras S, Petrone ME, Wille M, et al
    No evidence that mutations in SARS-CoV-2 variants of concern derive from homologous fragments in gut microbiota.
    J Virol. 2024 Nov 4:e0146824. doi: 10.1128/jvi.01468.
    PubMed     Abstract available
    
    
    October 2024
86. ZHANG C, Jiang Q, Liu Z, Li N, et al
    SARS-CoV-2 NSP6 reduces autophagosome size and affects viral replication via sigma-1 receptor.
    J Virol. 2024 Oct 24:e0075424. doi: 10.1128/jvi.00754.
    PubMed     Abstract available
    
    
    
87. SHAHRIARI S, Ghildyal R
    The actin-binding protein palladin associates with the respiratory syncytial virus matrix protein.
    J Virol. 2024;98:e0143524.
    PubMed     Abstract available
    
    
    
88. FAURE-DUPUY S, Depierre M, Fremont-Debaene Z, Herit F, et al
    Human rhinovirus 16 induces an ICAM-1-PKR-ATF2 axis to modulate macrophage functions.
    J Virol. 2024;98:e0149924.
    PubMed     Abstract available
    
    
    
89. HAN Y, Zhou H, Liu C, Wang W, et al
    SARS-CoV-2 N protein coordinates viral particle assembly through multiple domains.
    J Virol. 2024 Oct 16:e0103624. doi: 10.1128/jvi.01036.
    PubMed     Abstract available
    
    
    
90. TRIMARCO JD, Spurrier MA, Skavicus S, Luo Z, et al
    Fluorescent and bioluminescent bovine H5N1 influenza viruses for evaluation of antiviral interventions.
    J Virol. 2024 Oct 10:e0138524. doi: 10.1128/jvi.01385.
    PubMed     Abstract available
    
    
    
91. LI A, Zhao K, Duan Y, Zhang B, et al
    SARS-CoV-2 nsp13 suppresses hepatitis B virus replication by targeting cccDNA transcription.
    J Virol. 2024 Oct 7:e0104224. doi: 10.1128/jvi.01042.
    PubMed     Abstract available
    
    
    
92. WANG W, Bhushan G, Paz S, Stauft CB, et al
    Human and hamster sera correlate well in identifying antigenic drift among SARS-CoV-2 variants, including JN.1.
    J Virol. 2024 Oct 4:e0094824. doi: 10.1128/jvi.00948.
    PubMed     Abstract available
    
    
    
93. DO THT, Wille M, Wheatley AK, Koutsakos M, et al
    Triton X-100-treated virus-based ELLA demonstrates discordant antigenic evolution of influenza B virus hemagglutinin and neuraminidase.
    J Virol. 2024 Oct 3:e0118624. doi: 10.1128/jvi.01186.
    PubMed     Abstract available
    
    
    September 2024
94. HAMELE CE, Luo Z, Leonard RA, Spurrier MA, et al
    Headless hemagglutinin-containing influenza viral particles direct immune responses toward more conserved epitopes.
    J Virol. 2024 Sep 26:e0116624. doi: 10.1128/jvi.01166.
    PubMed     Abstract available
    
    
    
95. LOES AN, Tarabi RAL, Huddleston J, Touyon L, et al
    High-throughput sequencing-based neutralization assay reveals how repeated vaccinations impact titers to recent human H1N1 influenza strains.
    J Virol. 2024 Sep 24:e0068924. doi: 10.1128/jvi.00689.
    PubMed     Abstract available
    
    
    
96. DAVID SC, Schaub A, Terrettaz C, Motos G, et al
    Correction for David et al., "Stability of influenza A virus in droplets and aerosols is heightened by the presence of commensal respiratory bacteria".
    J Virol. 2024 Sep 19:e0122224. doi: 10.1128/jvi.01222.
    PubMed    
    
    
    
97. WANG Z, Qiu M, Ji Y, Chai K, et al
    Palmitoylation of SARS-CoV-2 Envelope protein is central to virus particle formation.
    J Virol. 2024 Sep 17:e0107224. doi: 10.1128/jvi.01072.
    PubMed     Abstract available
    
    
    
98. BROOKS K, Nelson CE, Aguilar C, Hoang TN, et al
    SARS-CoV-2 infection perturbs the gastrointestinal tract and induces modest microbial translocation across the intestinal barrier.
    J Virol. 2024 Sep 12:e0128824. doi: 10.1128/jvi.01288.
    PubMed     Abstract available
    
    
    
99. HAN M, Lu Q, Wang D, Zhou K, et al
    Oral co-administration of Lactiplantibacillus plantarum 16 and Lacticaseibacillus rhamnosus P118 improves host defense against influenza A virus infection.
    J Virol. 2024 Sep 11:e0095024. doi: 10.1128/jvi.00950.
    PubMed     Abstract available
    
    
    
100. SOUDANI N, Bricker TL, Darling T, Seehra K, et al
     Immunogenicity and efficacy of XBB.1.5 rS vaccine against the EG.5.1 variant of SARS-CoV-2 in Syrian hamsters.
     J Virol. 2024 Sep 4:e0052824. doi: 10.1128/jvi.00528.
     PubMed     Abstract available
     
     
     
101. GUAN M, DeLiberto TJ, Feng A, Zhang J, et al
     Neu5Gc binding loss of subtype H7 influenza A virus facilitates adaptation to gallinaceous poultry following transmission from waterbirds.
     J Virol. 2024 Sep 3:e0011924. doi: 10.1128/jvi.00119.
     PubMed     Abstract available
     
     
     August 2024
102. YANG Y, Xu C, Zhang N, Wan Y, et al
     Two amino acid residues in the N-terminal region of the polymerase acidic protein determine the virulence of Eurasian avian-like H1N1 swine influenza viruses in mice.
     J Virol. 2024 Aug 30:e0129324. doi: 10.1128/jvi.01293.
     PubMed     Abstract available
     
     
     
103. BARRETO-DURAN E, Synowiec A, Szczepanski A, Galuszka-Bulaga A, et al
     Development of an intestinal mucosa ex vivo co-culture model to study viral infections.
     J Virol. 2024 Aug 30:e0098724. doi: 10.1128/jvi.00987.
     PubMed     Abstract available
     
     
     
104. HU Y, Jin Y, Han D, Zhang G, et al
     Correction for Hu et al., "Mast Cell-Induced Lung Injury in Mice Infected with H5N1 Influenza Virus".
     J Virol. 2024 Aug 29:e0110624. doi: 10.1128/jvi.01106.
     PubMed    
     
     
     
105. ALFADHLI A, Bates TA, Barklis RL, Romanaggi C, et al
     A nanobody interaction with SARS-COV-2 Spike allows the versatile targeting of lentivirus vectors.
     J Virol. 2024 Aug 29:e0079524. doi: 10.1128/jvi.00795.
     PubMed     Abstract available
     
     
     
106. DMYTRENKO O, Das S, Kovacs A, Cicka M, et al
     Infiltrating monocytes drive cardiac dysfunction in a cardiomyocyte-restricted mouse model of SARS-CoV-2 infection.
     J Virol. 2024 Aug 29:e0117924. doi: 10.1128/jvi.01179.
     PubMed     Abstract available
     
     
     
107. LIEBER CM, Kang H-J, Sobolik EB, Sticher ZM, et al
     Efficacy of late-onset antiviral treatment in immunocompromised hosts with persistent SARS-CoV-2 infection.
     J Virol. 2024 Aug 29:e0090524. doi: 10.1128/jvi.00905.
     PubMed     Abstract available
     
     
     
108. GOODWIN E, Gibbs JS, Yewdell JW, Eisenlohr LC, et al
     Influenza virus antibodies inhibit antigen-specific de novo B cell responses in mice.
     J Virol. 2024 Aug 28:e0076624. doi: 10.1128/jvi.00766.
     PubMed     Abstract available
     
     
     
109. HARTWIG SM, Odle A, Wong L-YR, Meyerholz DK, et al
     Respiratory syncytial virus infection provides protection against severe acute respiratory syndrome coronavirus challenge.
     J Virol. 2024 Aug 28:e0066924. doi: 10.1128/jvi.00669.
     PubMed     Abstract available
     
     
     
110. YING B, Liang C-Y, Desai P, Scheaffer SM, et al
     Ipsilateral or contralateral boosting of mice with mRNA vaccines confers equivalent immunity and protection against a SARS-CoV-2 Omicron strain.
     J Virol. 2024 Aug 28:e0057424. doi: 10.1128/jvi.00574.
     PubMed     Abstract available
     
     
     
111. ZHU J, Liu G, Sayyad Z, Goins CM, et al
     ISGylation of the SARS-CoV-2 N protein by HERC5 impedes N oligomerization and thereby viral RNA synthesis.
     J Virol. 2024 Aug 28:e0086924. doi: 10.1128/jvi.00869.
     PubMed     Abstract available
     
     
     
112. TERASAKI K, Makino S
     Requirement of the N-terminal region of nonstructural protein 1 in cis for SARS-CoV-2 defective RNA replication.
     J Virol. 2024 Aug 28:e0090024. doi: 10.1128/jvi.00900.
     PubMed     Abstract available
     
     
     
113. WANG G, Verma AK, Guan X, Bu F, et al
     Pan-beta-coronavirus subunit vaccine prevents SARS-CoV-2 Omicron, SARS-CoV, and MERS-CoV challenge.
     J Virol. 2024 Aug 27:e0037624. doi: 10.1128/jvi.00376.
     PubMed     Abstract available
     
     
     
114. UNO N, Ebensen T, Guzman CA, Ross TM, et al
     Intranasal administration of octavalent next-generation influenza vaccine elicits protective immune responses against seasonal and pre-pandemic viruses.
     J Virol. 2024 Aug 22:e0035424. doi: 10.1128/jvi.00354.
     PubMed     Abstract available
     
     
     
115. WANG L, Shi L, Liu H, Zhang J, et al
     Incompatible packaging signals and impaired protein functions hinder reassortment of bat H17N10 or H18N11 segment 7 with human H1N1 influenza A viruses.
     J Virol. 2024 Aug 20:e0086424. doi: 10.1128/jvi.00864.
     PubMed     Abstract available
     
     
     
116. GAO Y, Raghavan A, Espinosa Garcia SA, Deng B, et al
     In vitro higher-order oligomeric assembly of the respiratory syncytial virus M2-1 protein with longer RNAs.
     J Virol. 2024;98:e0104624.
     PubMed     Abstract available
     
     
     
117. MUSA AO, Faber SR, Forrest K, Smith KP, et al
     Identification of distinct genotypes in circulating RSV A strains based on variants in the virus replication-associated genes.
     J Virol. 2024;98:e0099024.
     PubMed     Abstract available
     
     
     
118. BARBOSA BOMFIM CC, Genin H, Cottoignies-Callamarte A, Gallois-Montbrun S, et al
     CGRP inhibits SARS-CoV-2 infection of bronchial epithelial cells, and its pulmonary levels correlate with viral clearance in critical COVID-19 patients.
     J Virol. 2024 Aug 20:e0012824. doi: 10.1128/jvi.00128.
     PubMed     Abstract available
     
     
     
119. RHAMADIANTI AF, Abe T, Tanaka T, Ono C, et al
     SARS-CoV-2 papain-like protease inhibits ISGylation of the viral nucleocapsid protein to evade host anti-viral immunity.
     J Virol. 2024 Aug 9:e0085524. doi: 10.1128/jvi.00855.
     PubMed     Abstract available
     
     
     
120. ALWINE J, Goodrum F, Banfield B, Bloom D, et al
     The harms of promoting the lab leak hypothesis for SARS-CoV-2 origins without evidence.
     J Virol. 2024 Aug 1:e0124024. doi: 10.1128/jvi.01240.
     PubMed     Abstract available
     
     
     July 2024
121. AMOAH S, Cao W, Sayedahmed EE, Wang Y, et al
     The frequency and function of nucleoprotein-specific CD8(+) T cells are critical for heterosubtypic immunity against influenza virus infection.
     J Virol. 2024 Jul 31:e0071124. doi: 10.1128/jvi.00711.
     PubMed     Abstract available
     
     
     
122. WIGGINS KB, Winston SM, Reeves IL, Gaevert J, et al
     rAAV expressing a COBRA-designed influenza hemagglutinin generates a protective and durable adaptive immune response with a single dose.
     J Virol. 2024 Jul 30:e0078124. doi: 10.1128/jvi.00781.
     PubMed     Abstract available
     
     
     
123. SPACKMAN E, Jones DR, McCoig AM, Colonius TJ, et al
     Characterization of highly pathogenic avian influenza virus in retail dairy products in the US.
     J Virol. 2024 Jul 3:e0088124. doi: 10.1128/jvi.00881.
     PubMed     Abstract available
     
     
     
124. RICHARDSON SI, Mzindle N, Motlou T, Manamela NP, et al
     SARS-CoV-2 BA.4/5 infection triggers more cross-reactive FcgammaRIIIa signaling and neutralization than BA.1, in the context of hybrid immunity.
     J Virol. 2024 Jul 2:e0067824. doi: 10.1128/jvi.00678.
     PubMed     Abstract available
     
     
     June 2024
125. YU X, Tian J, Wang Y, Su N, et al
     The pseudogene GBP1P1 suppresses influenza A virus replication by acting as a protein decoy for DHX9.
     J Virol. 2024 Jun 28:e0073824. doi: 10.1128/jvi.00738.
     PubMed     Abstract available
     
     
     
126. PECHOUS RD, Malaviarachchi PA, Banerjee SK, Byrum SD, et al
     An ex vivo human precision-cut lung slice platform provides insight into SARS-CoV-2 pathogenesis and antiviral drug efficacy.
     J Virol. 2024 Jun 28:e0079424. doi: 10.1128/jvi.00794.
     PubMed     Abstract available
     
     
     
127. CHEN Z, Cui Q, Ran Y, Achi JG, et al
     A BSL-2 compliant mouse model of SARS-CoV-2 infection for efficient and convenient antiviral evaluation.
     J Virol. 2024 Jun 20:e0050424. doi: 10.1128/jvi.00504.
     PubMed     Abstract available
     
     
     
128. STAHL-HENNIG C, Peter AS, Cordsmeier A, Stolte-Leeb N, et al
     Genetic barrier to resistance: a critical parameter for efficacy of neutralizing monoclonal antibodies against SARS-CoV-2 in a nonhuman primate model.
     J Virol. 2024 Jun 20:e0062824. doi: 10.1128/jvi.00628.
     PubMed     Abstract available
     
     
     
129. PAN R, Li P, Meyerholz DK, Perlman S, et al
     Mutations in nonstructural proteins essential for pathogenicity in SARS-CoV-2-infected mice.
     J Virol. 2024 Jun 18:e0058424. doi: 10.1128/jvi.00584.
     PubMed     Abstract available
     
     
     
130. ZHU J, Wang Z, Li Y, Zhang Z, et al
     Trimerized S expressed by modified vaccinia virus Ankara (MVA) confers superior protection against lethal SARS-CoV-2 challenge in mice.
     J Virol. 2024 Jun 14:e0052124. doi: 10.1128/jvi.00521.
     PubMed     Abstract available
     
     
     
131. DAVID SC, Schaub A, Terrettaz C, Motos G, et al
     Stability of influenza A virus in droplets and aerosols is heightened by the presence of commensal respiratory bacteria.
     J Virol. 2024 Jun 13:e0040924. doi: 10.1128/jvi.00409.
     PubMed     Abstract available
     
     
     May 2024
132. HUANG Y, Owino SO, Crevar CJ, Carter DM, et al
     Correction for Huang et al., "N-Linked Glycans and K147 Residue on Hemagglutinin Synergize To Elicit Broadly Reactive H1N1 Influenza Virus Antibodies".
     J Virol. 2024 May 31:e0112823. doi: 10.1128/jvi.01128.
     PubMed    
     
     
     
133. CARTER DM, Darby CA, Lefoley BC, Crevar CJ, et al
     Correction for Carter et al., "Design and Characterization of a Computationally Optimized Broadly Reactive Hemagglutinin Vaccine for H1N1 Influenza Viruses".
     J Virol. 2024 May 31:e0181323. doi: 10.1128/jvi.01813.
     PubMed    
     
     
     
134. CARTER DM, Darby CA, Johnson SK, Carlock MA, et al
     Retraction for Carter et al., "Elicitation of Protective Antibodies against a Broad Panel of H1N1 Viruses in Ferrets Preimmune to Historical H1N1 Influenza Viruses".
     J Virol. 2024 May 31:e0183223. doi: 10.1128/jvi.01832.
     PubMed    
     
     
     
135. RAHMAN SM, Buchholz DW, Imbiakha B, Jager MC, et al
     Migraine inhibitor olcegepant reduces weight loss and IL-6 release in SARS-CoV-2-infected older mice with neurological signs.
     J Virol. 2024 May 30:e0006624. doi: 10.1128/jvi.00066.
     PubMed     Abstract available
     
     
     
136. MARIZZI C, Ajayi PK, McMahon R, Meade PS, et al
     A community science approach to public health and public trust in science.
     J Virol. 2024 May 29:e0082524. doi: 10.1128/jvi.00825.
     PubMed     Abstract available
     
     
     
137. KNOLL M, Honce R, Meliopoulos V, Segredo-Otero EA, et al
     Host obesity impacts genetic variation in influenza A viral populations.
     J Virol. 2024 May 24:e0177823. doi: 10.1128/jvi.01778.
     PubMed     Abstract available
     
     
     
138. SCHWAB LSU, Do THT, Pilapitiya D, Koutsakos M, et al
     Dissemination of influenza B virus to the lower respiratory tract of mice is restricted by the interferon response.
     J Virol. 2024 May 23:e0160423. doi: 10.1128/jvi.01604.
     PubMed     Abstract available
     
     
     
139. MA MT, Jiang Q, Chen C-H, Badeti S, et al
     S309-CAR-NK cells bind the Omicron variants in vitro and reduce SARS-CoV-2 viral loads in humanized ACE2-NSG mice.
     J Virol. 2024 May 20:e0003824. doi: 10.1128/jvi.00038.
     PubMed     Abstract available
     
     
     
140. MEADE PS, Bandawane P, Bushfield K, Hoxie I, et al
     Detection of clade 2.3.4.4b highly pathogenic H5N1 influenza virus in New York City.
     J Virol. 2024 May 15:e0062624. doi: 10.1128/jvi.00626.
     PubMed     Abstract available
     
     
     
141. CESAR RAMOS DE JESUS H, Solis N, Machado Y, Pablos I, et al
     Optimization of quenched fluorescent peptide substrates of SARS-CoV-2 3CL(pro) main protease (Mpro) from proteomic identification of P6-P6' active site specificity.
     J Virol. 2024 May 14:e0004924. doi: 10.1128/jvi.00049.
     PubMed     Abstract available
     
     
     
142. YU M, Li J, Gao W, Li Z, et al
     Multiple E3 ligases act as antiviral factors against SARS-CoV-2 via inducing the ubiquitination and degradation of ORF9b.
     J Virol. 2024 May 6:e0162423. doi: 10.1128/jvi.01624.
     PubMed     Abstract available
     
     
     April 2024
143. VIOX EG, Bosinger SE, Douek DC, Schreiber G, et al
     Harnessing the power of IFN for therapeutic approaches to COVID-19.
     J Virol. 2024 Apr 23:e0120423. doi: 10.1128/jvi.01204.
     PubMed     Abstract available
     
     
     
144. MAO D, Liu S, Phan AT, Renner S, et al
     The TRAF3-DYRK1A-RAD54L2 complex maintains ACE2 expression to promote SARS-CoV-2 infection.
     J Virol. 2024 Apr 23:e0034724. doi: 10.1128/jvi.00347.
     PubMed     Abstract available
     
     
     
145. HAN Y, Yuan Z, Yi Z
     Identification of a membrane-associated element (MAE) in the C-terminal region of SARS-CoV-2 nsp6 that is essential for viral replication.
     J Virol. 2024 Apr 19:e0034924. doi: 10.1128/jvi.00349.
     PubMed     Abstract available
     
     
     
146. BOUGON J, Kadijk E, Gallot-Lavallee L, Curtis BA, et al
     Influenza A virus NS1 effector domain is required for PA-X-mediated host shutoff in infected cells.
     J Virol. 2024 Apr 17:e0190123. doi: 10.1128/jvi.01901.
     PubMed     Abstract available
     
     
     
147. PEREZ DR
     A devastating blow: personal reflections on Argentina's scientific decline.
     J Virol. 2024 Apr 16:e0054924. doi: 10.1128/jvi.00549.
     PubMed     Abstract available
     
     
     
148. ISHIMARU H, Nishimura M, Shigematsu H, Marini MI, et al
     Epitopes of an antibody that neutralizes a wide range of SARS-CoV-2 variants in a conserved subdomain 1 of the spike protein.
     J Virol. 2024 Apr 16:e0041624. doi: 10.1128/jvi.00416.
     PubMed     Abstract available
     
     
     
149. TAKADA K, Orba Y, Kida Y, Wu J, et al
     Genes involved in the limited spread of SARS-CoV-2 in the lower respiratory airways of hamsters may be associated with adaptive evolution.
     J Virol. 2024 Apr 16:e0178423. doi: 10.1128/jvi.01784.
     PubMed     Abstract available
     
     
     
150. BU H, Zhang S, Li P, Liu Z, et al
     Secreted phospholipase PLA2G2E contributes to regulation of T cell immune response against influenza virus infection.
     J Virol. 2024 Apr 9:e0019824. doi: 10.1128/jvi.00198.
     PubMed     Abstract available
     
     
     
151. BOON ACM, Bricker TL, Fritch EJ, Leist SR, et al
     Efficacy of host cell serine protease inhibitor MM3122 against SARS-CoV-2 for treatment and prevention of COVID-19.
     J Virol. 2024 Apr 9:e0190323. doi: 10.1128/jvi.01903.
     PubMed     Abstract available
     
     
     
152. YANG R, Han P, Han P, Li D, et al
     Molecular basis of hippopotamus ACE2 binding to SARS-CoV-2.
     J Virol. 2024 Apr 9:e0045124. doi: 10.1128/jvi.00451.
     PubMed     Abstract available
     
     
     
153. XIAO X, Fu Y, You W, Huang C, et al
     Inhibition of the RLR signaling pathway by SARS-CoV-2 ORF7b is mediated by MAVS and abrogated by ORF7b-homologous interfering peptide.
     J Virol. 2024 Apr 4:e0157323. doi: 10.1128/jvi.01573.
     PubMed     Abstract available
     
     
     
154. MAES A, Botzki A, Mathys J, Impens F, et al
     Systematic review and meta-analysis of genome-wide pooled CRISPR screens to identify host factors involved in influenza A virus infection.
     J Virol. 2024 Apr 3:e0185723. doi: 10.1128/jvi.01857.
     PubMed     Abstract available
     
     
     
155. SILVA F, Boal-Carvalho I, Williams N, Chabert M, et al
     Identification of a short sequence motif in the influenza A virus pathogenicity factor PB1-F2 required for inhibition of human NLRP3.
     J Virol. 2024 Apr 3:e0041124. doi: 10.1128/jvi.00411.
     PubMed     Abstract available
     
     
     
156. KEOWN J, Baazaoui A, Sebesta M, Stefl R, et al
     Structural and functional characterization of the interaction between the influenza A virus RNA polymerase and the CTD of host RNA polymerase II.
     J Virol. 2024 Apr 2:e0013824. doi: 10.1128/jvi.00138.
     PubMed     Abstract available
     
     
     
157. BRUNET J, Choucha Z, Gransagne M, Tabbal H, et al
     A measles-vectored vaccine candidate expressing prefusion-stabilized SARS-CoV-2 spike protein brought to phase I/II clinical trials: candidate selection in a preclinical murine model.
     J Virol. 2024 Apr 2:e0169323. doi: 10.1128/jvi.01693.
     PubMed     Abstract available
     
     
     
158. NAMBULLI S, Escriou N, Rennick LJ, Demers MJ, et al
     A measles-vectored vaccine candidate expressing prefusion-stabilized SARS-CoV-2 spike protein brought to phase I/II clinical trials: protection of African green monkeys from COVID-19 disease.
     J Virol. 2024 Apr 2:e0176223. doi: 10.1128/jvi.01762.
     PubMed     Abstract available
     
     
     March 2024
159. MAI F, Bergmann W, Reisinger EC, Muller-Hilke B, et al
     The varying extent of humoral and cellular immune responses to either vector- or RNA-based SARS-CoV-2 vaccines persists for at least 18 months and is independent of infection.
     J Virol. 2024 Mar 19:e0191223. doi: 10.1128/jvi.01912.
     PubMed     Abstract available
     
     
     
160. BABOT M, Boulard Y, Agouda S, Pieri L, et al
     Oligomeric assembly of the C-terminal and transmembrane region of SARS-CoV-2 nsp3.
     J Virol. 2024 Mar 14:e0157523. doi: 10.1128/jvi.01575.
     PubMed     Abstract available
     
     
     
161. SPRUIT CM, Palme DI, Li T, Rios Carrasco M, et al
     Complex N-glycans are important for interspecies transmission of H7 influenza A viruses.
     J Virol. 2024 Mar 12:e0194123. doi: 10.1128/jvi.01941.
     PubMed     Abstract available
     
     
     
162. HEINDL MR, Rupp A-L, Schwerdtner M, Bestle D, et al
     ACE2 acts as a novel regulator of TMPRSS2-catalyzed proteolytic activation of influenza A virus in airway cells.
     J Virol. 2024 Mar 12:e0010224. doi: 10.1128/jvi.00102.
     PubMed     Abstract available
     
     
     
163. WEN F, Yan Z, Chen G, Chen Y, et al
     Recent H9N2 avian influenza virus lost hemagglutination activity due to a K141N substitution in hemagglutinin.
     J Virol. 2024 Mar 11:e0024824. doi: 10.1128/jvi.00248.
     PubMed     Abstract available
     
     
     
164. ZHENG T, Shen B, Bai Y, Li E, et al
     The PKA-CREB1 axis regulates coronavirus proliferation by viral helicase nsp13 association.
     J Virol. 2024 Mar 6:e0156523. doi: 10.1128/jvi.01565.
     PubMed     Abstract available
     
     
     February 2024
165. ZHANG M, Liu M, Chen H, Qiu T, et al
     PB2 residue 473 contributes to the mammalian virulence of H7N9 avian influenza virus by modulating viral polymerase activity via ANP32A.
     J Virol. 2024 Feb 29:e0194423. doi: 10.1128/jvi.01944.
     PubMed     Abstract available
     
     
     
166. MARTINS M, Nooruzzaman M, Cunningham JL, Ye C, et al
     The SARS-CoV-2 Spike is a virulence determinant and plays a major role on the attenuated phenotype of Omicron virus in a feline model of infection.
     J Virol. 2024 Feb 29:e0190223. doi: 10.1128/jvi.01902.
     PubMed     Abstract available
     
     
     
167. HAN J, Chang W, Fang J, Hou X, et al
     The H9N2 avian influenza virus increases APEC adhesion to oviduct epithelia by viral NS1 protein-mediated activation of the TGF-beta pathway.
     J Virol. 2024 Feb 28:e0151223. doi: 10.1128/jvi.01512.
     PubMed     Abstract available
     
     
     
168. UPRETY T, Yu J, Nogales A, Naveed A, et al
     Influenza D virus utilizes both 9-O-acetylated N-acetylneuraminic and 9-O-acetylated N-glycolylneuraminic acids as functional entry receptors.
     J Virol. 2024 Feb 20:e0004224. doi: 10.1128/jvi.00042.
     PubMed     Abstract available
     
     
     
169. NIE L, Huang Y, Cheng Z, Luo H, et al
     An intranasal influenza virus vector vaccine protects against Helicobacter pylori in mice.
     J Virol. 2024 Feb 15:e0192323. doi: 10.1128/jvi.01923.
     PubMed     Abstract available
     
     
     
170. ZENG J, Du F, Xiao L, Sun H, et al
     Spatiotemporal genotype replacement of H5N8 avian influenza viruses contributed to H5N1 emergence in 2021/2022 panzootic.
     J Virol. 2024 Feb 15:e0140123. doi: 10.1128/jvi.01401.
     PubMed     Abstract available
     
     
     
171. THOMAS MN, Zanella GC, Cowan B, Caceres CJ, et al
     Nucleoprotein reassortment enhanced transmissibility of H3 1990.4.a clade influenza A virus in swine.
     J Virol. 2024 Feb 14:e0170323. doi: 10.1128/jvi.01703.
     PubMed     Abstract available
     
     
     
172. KATAYAMA M, Murakami S, Ishida H, Matsugo H, et al
     Antigenic commonality and divergence of hemagglutinin-esterase-fusion protein among influenza D virus lineages revealed using epitope mapping.
     J Virol. 2024 Feb 12:e0190823. doi: 10.1128/jvi.01908.
     PubMed     Abstract available
     
     
     
173. VANSLAMBROUCK JM, Neil JA, Rudraraju R, Mah S, et al
     Kidney organoids reveal redundancy in viral entry pathways during ACE2-dependent SARS-CoV-2 infection.
     J Virol. 2024 Feb 9:e0180223. doi: 10.1128/jvi.01802.
     PubMed     Abstract available
     
     
     
174. SHINGAI M, Iida S, Kawai N, Kawahara M, et al
     Extraction of the CDRH3 sequence of the mouse antibody repertoire selected upon influenza virus infection by subtraction of the background antibody repertoire.
     J Virol. 2024 Feb 7:e0199523. doi: 10.1128/jvi.01995.
     PubMed     Abstract available
     
     
     
175. YANG Q, Barbachano-Guerrero A, Fairchild LM, Rowland TJ, et al
     Macrophages derived from human induced pluripotent stem cells (iPSCs) serve as a high-fidelity cellular model for investigating HIV-1, dengue, and influenza viruses.
     J Virol. 2024 Feb 7:e0156323. doi: 10.1128/jvi.01563.
     PubMed     Abstract available
     
     
     
176. LI H, Sun H, Tao M, Han Q, et al
     Recombinant parainfluenza virus 5 expressing clade 2.3.4.4b H5 hemagglutinin protein confers broad protection against H5Ny influenza viruses.
     J Virol. 2024 Feb 2:e0112923. doi: 10.1128/jvi.01129.
     PubMed     Abstract available
     
     
     
177. NIU S, Zhao Z, Liu Z, Rong X, et al
     Structural basis and analysis of hamster ACE2 binding to different SARS-CoV-2 spike RBDs.
     J Virol. 2024 Feb 2:e0115723. doi: 10.1128/jvi.01157.
     PubMed     Abstract available
     
     
     
178. BRICKER TL, Joshi A, Soudani N, Scheaffer SM, et al
     Prototype and BA.5 protein nanoparticle vaccines protect against Omicron BA.5 variant in Syrian hamsters.
     J Virol. 2024 Feb 2:e0120623. doi: 10.1128/jvi.01206.
     PubMed     Abstract available
     
     
     
179. HSIEH M-S, Hsu C-W, Liao H-C, Lin C-L, et al
     SARS-CoV-2 spike-FLIPr fusion protein plus lipidated FLIPr protects against various SARS-CoV-2 variants in hamsters.
     J Virol. 2024 Feb 1:e0154623. doi: 10.1128/jvi.01546.
     PubMed     Abstract available
     
     
     January 2024
180. ROWE T, Davis W, Wentworth DE, Ross T, et al
     Differential interferon responses to influenza A and B viruses in primary ferret respiratory epithelial cells.
     J Virol. 2024 Jan 31:e0149423. doi: 10.1128/jvi.01494.
     PubMed     Abstract available
     
     
     
181. SHEN S, Guo H, Li Y, Zhang L, et al
     SARS-CoV-2 and oncolytic EV-D68-encoded proteases differentially regulate pyroptosis.
     J Virol. 2024 Jan 30:e0190923. doi: 10.1128/jvi.01909.
     PubMed     Abstract available
     
     
     
182. KIERAN TJ, Sun X, Maines TR, Beauchemin CAA, et al
     Exploring associations between viral titer measurements and disease outcomes in ferrets inoculated with 125 contemporary influenza A viruses.
     J Virol. 2024 Jan 19:e0166123. doi: 10.1128/jvi.01661.
     PubMed     Abstract available
     
     
     
183. DULIN H, Barre RS, Xu D, Neal A, et al
     Harnessing preexisting influenza virus-specific immunity increases antibody responses against SARS-CoV-2.
     J Virol. 2024 Jan 11:e0157123. doi: 10.1128/jvi.01571.
     PubMed     Abstract available
     
     
     
184. HE Y, Guo Z, Subiaur S, Benegal A, et al
     Antibody inhibition of influenza A virus assembly and release.
     J Virol. 2024 Jan 5:e0139823. doi: 10.1128/jvi.01398.
     PubMed     Abstract available
     
     
     
185. DEY S, Mondal A
     Unveiling the role of host kinases at different steps of influenza A virus life cycle.
     J Virol. 2024 Jan 4:e0119223. doi: 10.1128/jvi.01192.
     PubMed     Abstract available
     
     
     
186. FARJO M, Koelle K, Martin MA, Gibson LL, et al
     Within-host evolutionary dynamics and tissue compartmentalization during acute SARS-CoV-2 infection.
     J Virol. 2024 Jan 4:e0161823. doi: 10.1128/jvi.01618.
     PubMed     Abstract available
     
     
     
187. LI K, Verma A, Li P, Ortiz ME, et al
     Adaptation of SARS-CoV-2 to ACE2(H353K) mice reveals new spike residues that drive mouse infection.
     J Virol. 2024 Jan 3:e0151023. doi: 10.1128/jvi.01510.
     PubMed     Abstract available
     
     
     
188. RASMUSSEN AL, Gronvall GK, Lowen AC, Goodrum F, et al
     Virology-the path forward.
     J Virol. 2024 Jan 3:e0179123. doi: 10.1128/jvi.01791.
     PubMed     Abstract available
     
     
     December 2023
189. BOLLAND W, Michel V, Planas D, Hubert M, et al
     High fusion and cytopathy of SARS-CoV-2 variant B.1.640.1.
     J Virol. 2023 Dec 13:e0135123. doi: 10.1128/jvi.01351.
     PubMed     Abstract available
     
     
     
190. JERONIMO PMC, Aksenen CF, Duarte IO, Lins RD, et al
     Evolutionary deletions within the SARS-CoV-2 genome as signature trends for virus fitness and adaptation.
     J Virol. 2023 Dec 13:e0140423. doi: 10.1128/jvi.01404.
     PubMed     Abstract available
     
     
     
191. ZHANG L, Shao Y, Wang Y, Yang Q, et al
     Twenty natural amino acid substitution screening at the last residue 121 of influenza A virus NS2 protein reveals the critical role of NS2 in promoting virus genome replication by coordinating with viral polymerase.
     J Virol. 2023 Dec 6:e0116623. doi: 10.1128/jvi.01166.
     PubMed     Abstract available
     
     
     
192. PHAM TX, Huynh TTX, Choi J, Lee J-B, et al
     SARS-CoV-2 exploits cellular RAD51 to promote viral propagation: implication of RAD51 inhibitor as a potential drug candidate against COVID-19.
     J Virol. 2023 Dec 5:e0173723. doi: 10.1128/jvi.01737.
     PubMed     Abstract available
     
     
     
193. ZAYOU L, Prakash S, Dhanushkodi NR, Quadiri A, et al
     A multi-epitope/CXCL11 prime/pull coronavirus mucosal vaccine boosts the frequency and the function of lung-resident memory CD4(+) and CD8(+) T cells and enhanced protection against COVID-19-like symptoms and death caused by SARS-CoV-2 infection.
     J Virol. 2023 Dec 1:e0109623. doi: 10.1128/jvi.01096.
     PubMed     Abstract available
     
     
     November 2023
194. LI K, Huntwork RHC, Horn GQ, Abraha M, et al
     Cryptic-site-specific antibodies to the SARS-CoV-2 receptor binding domain can retain functional binding affinity to spike variants.
     J Virol. 2023 Nov 29:e0107023. doi: 10.1128/jvi.01070.
     PubMed     Abstract available
     
     
     
195. DOMINGO E, Martinez-Gonzalez B, Garcia-Crespo C, Somovilla P, et al
     Puzzles, challenges, and information reservoir of SARS-CoV-2 quasispecies.
     J Virol. 2023 Nov 21:e0151123. doi: 10.1128/jvi.01511.
     PubMed     Abstract available
     
     
     
196. BRAGAZZI CUNHA J, Leix K, Sherman EJ, Mirabelli C, et al
     Type I interferon signaling induces a delayed antiproliferative response in respiratory epithelial cells during SARS-CoV-2 infection.
     J Virol. 2023 Nov 17:e0127623. doi: 10.1128/jvi.01276.
     PubMed     Abstract available
     
     
     
197. ALRUWAILI M, Armstrong S, Prince T, Erdmann M, et al
     SARS-CoV-2 NSP12 associates with TRiC and the P323L substitution acts as a host adaption.
     J Virol. 2023 Nov 6:e0042423. doi: 10.1128/jvi.00424.
     PubMed     Abstract available
     
     
     
198. SUN W, Xu J, Wang Z, Li D, et al
     Clade 2.3.4.4 H5 chimeric cold-adapted attenuated influenza vaccines induced cross-reactive protection in mice and ferrets.
     J Virol. 2023 Nov 2:e0110123. doi: 10.1128/jvi.01101.
     PubMed     Abstract available
     
     
     
199. RIJNINK WF, Stadlbauer D, Puente-Massaguer E, Okba NMA, et al
     Characterization of non-neutralizing human monoclonal antibodies that target the M1 and NP of influenza A viruses.
     J Virol. 2023 Nov 2:e0164622. doi: 10.1128/jvi.01646.
     PubMed     Abstract available
     
     
     October 2023
200. PAHMEIER F, Lavacca T-M, Goellner S, Neufeldt CJ, et al
     Identification of host dependency factors involved in SARS-CoV-2 replication organelle formation through proteomics and ultrastructural analysis.
     J Virol. 2023 Oct 31:e0087823. doi: 10.1128/jvi.00878.
     PubMed     Abstract available
     
     
     
201. CAO J, Shi M, Zhu L, Li X, et al
     The matrix protein of respiratory syncytial virus suppresses interferon signaling via RACK1 association.
     J Virol. 2023;97:e0074723.
     PubMed     Abstract available
     
     
     
202. BARTSCH YC, Cizmeci D, Yuan D, Mehta N, et al
     Vaccine-induced antibody Fc-effector functions in humans immunized with a combination Ad26.RSV.preF/RSV preF protein vaccine.
     J Virol. 2023 Oct 30:e0077123. doi: 10.1128/jvi.00771.
     PubMed     Abstract available
     
     
     
203. LI Y, Arcos S, Sabsay KR, Te Velthuis AJW, et al
     Deep mutational scanning reveals the functional constraints and evolutionary potential of the influenza A virus PB1 protein.
     J Virol. 2023 Oct 26:e0132923. doi: 10.1128/jvi.01329.
     PubMed     Abstract available
     
     
     
204. YAN Z, Li Y, Huang S, Wen F, et al
     Global distribution, receptor binding, and cross-species transmission of H6 influenza viruses: risks and implications for humans.
     J Virol. 2023 Oct 25:e0137023. doi: 10.1128/jvi.01370.
     PubMed     Abstract available
     
     
     
205. UNDI RB, Ahsan N, Larabee JL, Darlene-Reuter N, et al
     Blocking of doublecortin-like kinase 1-regulated SARS-CoV-2 replication cycle restores cell signaling network.
     J Virol. 2023 Oct 20:e0119423. doi: 10.1128/jvi.01194.
     PubMed     Abstract available
     
     
     
206. KUMAR S, Delipan R, Chakraborty D, Kanjo K, et al
     Mutations in S2 subunit of SARS-CoV-2 Omicron spike strongly influence its conformation, fusogenicity, and neutralization sensitivity.
     J Virol. 2023 Oct 20:e0092223. doi: 10.1128/jvi.00922.
     PubMed     Abstract available
     
     
     
207. YE G, Pan R, Bu F, Zheng J, et al
     Discovery of Nanosota-2, -3, and -4 as super potent and broad-spectrum therapeutic nanobody candidates against COVID-19.
     J Virol. 2023 Oct 19:e0144823. doi: 10.1128/jvi.01448.
     PubMed     Abstract available
     
     
     
208. SUN H, Wang Y, Chen X, Jiang Y, et al
     Structural basis for broad neutralization of human antibody against Omicron sublineages and evasion by XBB variant.
     J Virol. 2023 Oct 19:e0113723. doi: 10.1128/jvi.01137.
     PubMed     Abstract available
     
     
     
209. JOHNSON RM, Ardanuy J, Hammond H, Logue J, et al
     Diet-induced obesity and diabetes enhance mortality and reduce vaccine efficacy for SARS-CoV-2.
     J Virol. 2023 Oct 17:e0133623. doi: 10.1128/jvi.01336.
     PubMed     Abstract available
     
     
     
210. LIANG CY, Huang I, Han J, Sownthirarajan B, et al
     Avian influenza A viruses exhibit plasticity in sialylglycoconjugate receptor usage in human lung cells.
     J Virol. 2023 Oct 16:e0090623. doi: 10.1128/jvi.00906.
     PubMed     Abstract available
     
     
     
211. WU Y, Shi J, He X, Lu J, et al
     Protection of the receptor binding domain (RBD) dimer against SARS-CoV-2 and its variants.
     J Virol. 2023 Oct 16:e0127923. doi: 10.1128/jvi.01279.
     PubMed     Abstract available
     
     
     
212. MISPLON JA, Lo CY, Crabbs TA, Price GE, et al
     Adenoviral-vectored universal influenza vaccines administered intranasally reduce lung inflammatory responses upon viral challenge 15 months post-vaccination.
     J Virol. 2023 Oct 13:e0067423. doi: 10.1128/jvi.00674.
     PubMed     Abstract available
     
     
     
213. MIURA K, Suzuki Y, Ishida K, Arakawa M, et al
     Distinct motifs in the E protein are required for SARS-CoV-2 virus particle formation and lysosomal deacidification in host cells.
     J Virol. 2023 Oct 13:e0042623. doi: 10.1128/jvi.00426.
     PubMed     Abstract available
     
     
     
214. MAHE D, Bourgeau S, da Silva J, Schlederer J, et al
     SARS-CoV-2 replicates in the human testis with slow kinetics and has no major deleterious effects ex vivo.
     J Virol. 2023 Oct 13:e0110423. doi: 10.1128/jvi.01104.
     PubMed     Abstract available
     
     
     
215. RIBO-MOLINA P, Weiss HJ, Susma B, van Nieuwkoop S, et al
     4-Octyl itaconate reduces influenza A replication by targeting the nuclear export protein CRM1.
     J Virol. 2023 Oct 12:e0132523. doi: 10.1128/jvi.01325.
     PubMed     Abstract available
     
     
     
216. ISELI AN, Pohl MO, Glas I, Gaggioli E, et al
     The neuraminidase activity of influenza A virus determines the strain-specific sensitivity to neutralization by respiratory mucus.
     J Virol. 2023 Oct 11:e0127123. doi: 10.1128/jvi.01271.
     PubMed     Abstract available
     
     
     
217. GIRARD J, Jakob C, Toews LK, Fuchs J, et al
     Disruption of influenza virus packaging signals results in various misassembled genome complexes.
     J Virol. 2023 Oct 9:e0107623. doi: 10.1128/jvi.01076.
     PubMed     Abstract available
     
     
     
218. CARNACCINI S, Caceres CJ, Gay LC, Ferreri LM, et al
     Antigenic mapping of the hemagglutinin of the H9 subtype influenza A viruses using sera from Japanese quail (Coturnix c. japonica).
     J Virol. 2023 Oct 6:e0074323. doi: 10.1128/jvi.00743.
     PubMed     Abstract available
     
     
     
219. MCMAHON M, Tan J, O'Dell G, Kirkpatrick Roubidoux E, et al
     Immunity induced by vaccination with recombinant influenza B virus neuraminidase protein breaks viral transmission chains in guinea pigs in an exposure intensity-dependent manner.
     J Virol. 2023 Oct 6:e0105723. doi: 10.1128/jvi.01057.
     PubMed     Abstract available
     
     
     
220. KIMURA I, Yamasoba D, Nasser H, Ito H, et al
     Multiple mutations of SARS-CoV-2 Omicron BA.2 variant orchestrate its virological characteristics.
     J Virol. 2023 Oct 5:e0101123. doi: 10.1128/jvi.01011.
     PubMed     Abstract available
     
     
     
221. MENG X, Veit M
     Palmitoylation of the hemagglutinin of influenza B virus by ER-localized DHHC enzymes 1, 2, 4, and 6 is required for efficient virus replication.
     J Virol. 2023 Oct 4:e0124523. doi: 10.1128/jvi.01245.
     PubMed     Abstract available
     
     
     September 2023
222. ZHAO Y, Sui L, Wu P, Li L, et al
     EGR1 functions as a new host restriction factor for SARS-CoV-2 to inhibit virus replication through the E3 ubiquitin ligase MARCH8.
     J Virol. 2023 Sep 29:e0102823. doi: 10.1128/jvi.01028.
     PubMed     Abstract available
     
     
     
223. LI J, Gui Q, Liang FX, Sall J, et al
     The REEP5/TRAM1 complex binds SARS-CoV-2 NSP3 and promotes virus replication.
     J Virol. 2023 Sep 28:e0050723. doi: 10.1128/jvi.00507.
     PubMed     Abstract available
     
     
     
224. NENNA R, Stern DA, Carr TF, Spangenberg A, et al
     Prenatal exposure to RSV season influences first-year risk of RSV lower respiratory illness and RSV-specific immune responses assessed at birth.
     J Virol. 2023;97:e0076723.
     PubMed     Abstract available
     
     
     
225. WALLACE LE, de Vries E, van Kuppeveld FJM, de Haan CAM, et al
     Neuraminidase-dependent entry of influenza A virus is determined by hemagglutinin receptor-binding specificity.
     J Virol. 2023 Sep 27:e0060223. doi: 10.1128/jvi.00602.
     PubMed     Abstract available
     
     
     
226. MCCOOL RS, Musayev M, Bush SM, Derrien-Colemyn A, et al
     Vaccination with prefusion-stabilized respiratory syncytial virus fusion protein elicits antibodies targeting a membrane-proximal epitope.
     J Virol. 2023 Sep 22:e0092923. doi: 10.1128/jvi.00929.
     PubMed     Abstract available
     
     
     
227. SCHOEN A, Holzer M, Muller MA, Wallerang KB, et al
     Functional comparisons of the virus sensor RIG-I from humans, the microbat Myotis daubentonii, and the megabat Rousettus aegyptiacus, and their response to SARS-CoV-2 infection.
     J Virol. 2023 Sep 20:e0020523. doi: 10.1128/jvi.00205.
     PubMed     Abstract available
     
     
     
228. FUJITA S, Kosugi Y, Kimura I, Tokunaga K, et al
     Determination of the factors responsible for the tropism of SARS-CoV-2-related bat coronaviruses to Rhinolophus bat ACE2.
     J Virol. 2023 Sep 19:e0099023. doi: 10.1128/jvi.00990.
     PubMed     Abstract available
     
     
     
229. XING M, Wang Y, Wang X, Liu J, et al
     Broad-spectrum vaccine via combined immunization routes triggers potent immunity to SARS-CoV-2 and its variants.
     J Virol. 2023 Sep 14:e0072423. doi: 10.1128/jvi.00724.
     PubMed     Abstract available
     
     
     
230. CASE JB, Scheaffer SM, Darling TL, Bricker TL, et al
     Characterization of the SARS-CoV-2 BA.5.5 and BQ.1.1 Omicron variants in mice and hamsters.
     J Virol. 2023 Sep 7:e0062823. doi: 10.1128/jvi.00628.
     PubMed     Abstract available
     
     
     August 2023
231. LIN HF, Liu MQ, Jiang RD, Gong QC, et al
     Characterization of a mouse-adapted strain of bat severe acute respiratory syndrome-related coronavirus.
     J Virol. 2023 Aug 21:e0079023. doi: 10.1128/jvi.00790.
     PubMed     Abstract available
     
     
     
232. LEONARD RA, Rao VN, Bartlett A, Froggatt HM, et al
     A low-background, fluorescent assay to evaluate inhibitors of diverse viral proteases.
     J Virol. 2023 Aug 14:e0059723. doi: 10.1128/jvi.00597.
     PubMed     Abstract available
     
     
     
233. JIN H, Cheng L, Gong Y, Zhu Y, et al
     Design of a bifunctional pan-sarbecovirus entry inhibitor targeting the cell receptor and viral fusion protein.
     J Virol. 2023 Aug 14:e0019223. doi: 10.1128/jvi.00192.
     PubMed     Abstract available
     
     
     
234. ZHANG W, Shi K, Geng Q, Herbst M, et al
     Structural evolution of SARS-CoV-2 omicron in human receptor recognition.
     J Virol. 2023 Aug 14:e0082223. doi: 10.1128/jvi.00822.
     PubMed     Abstract available
     
     
     
235. LLEWELLYN GN, Chen HY, Rogers GL, Huang X, et al
     Comparison of SARS-CoV-2 entry inhibitors based on ACE2 receptor or engineered Spike-binding peptides.
     J Virol. 2023 Aug 9:e0068423. doi: 10.1128/jvi.00684.
     PubMed     Abstract available
     
     
     
236. MYKYTYN AZ, Breugem TI, Geurts MH, Beumer J, et al
     SARS-CoV-2 Omicron entry is type II transmembrane serine protease-mediated in human airway and intestinal organoid models.
     J Virol. 2023 Aug 9:e0085123. doi: 10.1128/jvi.00851.
     PubMed     Abstract available
     
     
     
237. THOMPSON D, Cismaru CV, Rougier JS, Schwemmle M, et al
     The M2 proteins of bat influenza A viruses reveal atypical features compared to conventional M2 proteins.
     J Virol. 2023 Aug 4:e0038823. doi: 10.1128/jvi.00388.
     PubMed     Abstract available
     
     
     July 2023
238. TALUKDAR SN, McGregor B, Osan JK, Hur J, et al
     Respiratory Syncytial Virus Infection Does Not Induce Epithelial-Mesenchymal Transition.
     J Virol. 2023;97:e0039423.
     PubMed     Abstract available
     
     
     
239. HICKERSON BT, Petrovskaya SN, Dickensheets H, Donnelly RP, et al
     Impact of Baloxavir Resistance-Associated Substitutions on Influenza Virus Growth and Drug Susceptibility.
     J Virol. 2023 Jul 5:e0015423. doi: 10.1128/jvi.00154.
     PubMed     Abstract available
     
     
     
240. JENSEN JL, Sankhala RS, Dussupt V, Bai H, et al
     Targeting the Spike Receptor Binding Domain Class V Cryptic Epitope by an Antibody with Pan-Sarbecovirus Activity.
     J Virol. 2023 Jul 3:e0159622. doi: 10.1128/jvi.01596.
     PubMed     Abstract available
     
     
     June 2023
241. HUANG J, Chen Z, Ye Y, Shao Y, et al
     DTX3L Enhances Type I Interferon Antiviral Response by Promoting the Ubiquitination and Phosphorylation of TBK1.
     J Virol. 2023;97:e0068723.
     PubMed     Abstract available
     
     
     
242. YANG X, Duan H, Liu X, Zhang X, et al
     Broad Sarbecovirus Neutralizing Antibodies Obtained by Computational Design and Synthetic Library Screening.
     J Virol. 2023 Jun 27:e0061023. doi: 10.1128/jvi.00610.
     PubMed     Abstract available
     
     
     
243. TERASAKI K, Narayanan K, Makino S
     Identification of a 1.4-kb-Long Sequence Located in the nsp12 and nsp13 Coding Regions of SARS-CoV-2 Genomic RNA That Mediates Efficient Viral RNA Packaging.
     J Virol. 2023 Jun 27:e0065923. doi: 10.1128/jvi.00659.
     PubMed     Abstract available
     
     
     
244. LI A, Zhang B, Zhao K, Yin Z, et al
     SARS-CoV-2 nsp13 Restricts Episomal DNA Transcription without Affecting Chromosomal DNA.
     J Virol. 2023 Jun 22:e0051223. doi: 10.1128/jvi.00512.
     PubMed     Abstract available
     
     
     
245. GOFFIN E, Du X, Hemmi S, Machiels B, et al
     A Single Oral Immunization with a Replication-Competent Adenovirus-Vectored Vaccine Protects Mice from Influenza Respiratory Infection.
     J Virol. 2023 Jun 20:e0013523. doi: 10.1128/jvi.00135.
     PubMed     Abstract available
     
     
     
246. CHEN P, Jin Z, Peng L, Zheng Z, et al
     Characterization of an Emergent Chicken H3N8 Influenza Virus in Southern China: a Potential Threat to Public Health.
     J Virol. 2023 Jun 8:e0043423. doi: 10.1128/jvi.00434.
     PubMed     Abstract available
     
     
     
247. ZHENG H, Ma L, Gui R, Lin X, et al
     Correction for Zheng et al., "G Protein Subunit beta1 Facilitates Influenza A Virus Replication by Promoting the Nuclear Import of PB2".
     J Virol. 2023 Jun 6:e0054623. doi: 10.1128/jvi.00546.
     PubMed    
     
     
     May 2023
248. WANG C, Honce R, Salvatore M, Chow D, et al
     Influenza Defective Interfering Virus Promotes Multiciliated Cell Differentiation and Reduces the Inflammatory Response in Mice.
     J Virol. 2023 May 31:e0049323. doi: 10.1128/jvi.00493.
     PubMed     Abstract available
     
     
     
249. RUNSTADLER JA, Lowen AC, Kayali G, Tompkins SM, et al
     Field Research Is Essential to Counter Virological Threats.
     J Virol. 2023;97:e0054423.
     PubMed     Abstract available
     
     
     
250. REZENDE W, Ye X, Angelo LS, Carisey AF, et al
     The Efficiency of p27 Cleavage during In Vitro Respiratory Syncytial Virus (RSV) Infection Is Cell Line and RSV Subtype Dependent.
     J Virol. 2023;97:e0025423.
     PubMed     Abstract available
     
     
     
251. SREENIVASAN CC, Liu R, Gao R, Guo Y, et al
     Influenza C and D Viruses Demonstrated a Differential Respiratory Tissue Tropism in a Comparative Pathogenesis Study in Guinea Pigs.
     J Virol. 2023 May 18:e0035623. doi: 10.1128/jvi.00356.
     PubMed     Abstract available
     
     
     
252. JIANG H, Joshi A, Gan T, Janowski AB, et al
     The Highly Conserved Stem-Loop II Motif Is Dispensable for SARS-CoV-2.
     J Virol. 2023 May 18:e0063523. doi: 10.1128/jvi.00635.
     PubMed     Abstract available
     
     
     
253. SLANINA H, Madhugiri R, Wenk K, Reinke T, et al
     Conserved Characteristics of NMPylation Activities of Alpha- and Betacoronavirus NiRAN Domains.
     J Virol. 2023 May 18:e0046523. doi: 10.1128/jvi.00465.
     PubMed     Abstract available
     
     
     
254. ISHIMARU H, Nishimura M, Tjan LH, Sutandhio S, et al
     Identification and Analysis of Monoclonal Antibodies with Neutralizing Activity against Diverse SARS-CoV-2 Variants.
     J Virol. 2023 May 16:e0028623. doi: 10.1128/jvi.00286.
     PubMed     Abstract available
     
     
     
255. ZHANG L, Wang Y, Shao Y, Guo J, et al
     Fine Regulation of Influenza Virus RNA Transcription and Replication by Stoichiometric Changes in Viral NS1 and NS2 Proteins.
     J Virol. 2023 May 11:e0033723. doi: 10.1128/jvi.00337.
     PubMed     Abstract available
     
     
     
256. SENGAR A, Cervantes M, Bondalapati ST, Hess T, et al
     Single-Virus Fusion Measurements Reveal Multiple Mechanistically Equivalent Pathways for SARS-CoV-2 Entry.
     J Virol. 2023 May 3:e0199222. doi: 10.1128/jvi.01992.
     PubMed     Abstract available
     
     
     April 2023
257. SPECK P, Mackenzie J, Bull RA, Slobedman B, et al
     Statement in Support of: "Virology under the Microscope-a Call for Rational Discourse".
     J Virol. 2023 Apr 25:e0045123. doi: 10.1128/jvi.00451.
     PubMed    
     
     
     
258. PEACOCK TP, Sheppard CM, Lister MG, Staller E, et al
     Mammalian ANP32A and ANP32B Proteins Drive Differential Polymerase Adaptations in Avian Influenza Virus.
     J Virol. 2023 Apr 19:e0021323. doi: 10.1128/jvi.00213.
     PubMed     Abstract available
     
     
     
259. KETTUNEN P, Lesnikova A, Rasanen N, Ojha R, et al
     SARS-CoV-2 Infection of Human Neurons Is TMPRSS2 Independent, Requires Endosomal Cell Entry, and Can Be Blocked by Inhibitors of Host Phosphoinositol-5 Kinase.
     J Virol. 2023 Apr 11:e0014423. doi: 10.1128/jvi.00144.
     PubMed     Abstract available
     
     
     
260. LIN SJ, Lin KM, Chen SJ, Ku CC, et al
     Type I Interferon Orchestrates Demand-Adapted Monopoiesis during Influenza A Virus Infection via STAT1-Mediated Upregulation of Macrophage Colony-Stimulating Factor Receptor Expression.
     J Virol. 2023 Apr 6:e0010223. doi: 10.1128/jvi.00102.
     PubMed     Abstract available
     
     
     March 2023
261. TAN Y, Shilts MH, Rosas-Salazar C, Puri V, et al
     Influence of Sex on Respiratory Syncytial Virus Genotype Infection Frequency and Nasopharyngeal Microbiome.
     J Virol. 2023;97:e0147222.
     PubMed     Abstract available
     
     
     
262. ALWINE JC, Casadevall A, Enquist LW, Goodrum FD, et al
     A critical analysis of the evidence for the SARS-CoV-2 origin hypotheses.
     J Virol. 2023 Mar 10:e0036523. doi: 10.1128/jvi.00365.
     PubMed     Abstract available
     
     
     
263. WANG X, Wang W, Wang T, Wang J, et al
     SARS-CoV-2 ORF8 Protein Induces Endoplasmic Reticulum Stress-like Responses and Facilitates Virus Replication by Triggering Calnexin: an Unbiased Study.
     J Virol. 2023 Mar 6:e0001123. doi: 10.1128/jvi.00011.
     PubMed     Abstract available
     
     
     
264. MOLS VC, Lamers MM, Leijten LM, Breugem TI, et al
     Intestinal Tropism of a Betacoronavirus (Merbecovirus) in Nathusius's Pipistrelle Bat (Pipistrellus nathusii), Its Natural Host.
     J Virol. 2023 Mar 1:e0009923. doi: 10.1128/jvi.00099.
     PubMed     Abstract available
     
     
     February 2023
265. FROLOV I, Agback T, Palchevska O, Dominguez F, et al
     All Domains of SARS-CoV-2 nsp1 Determine Translational Shutoff and Cytotoxicity of the Protein.
     J Virol. 2023 Feb 27:e0186522. doi: 10.1128/jvi.01865.
     PubMed     Abstract available
     
     
     
266. ZHANG L, Hom N, Ojha A, Lovendahl KN, et al
     Cytoplasmic Tail Truncation Stabilizes S1-S2 Association and Enhances S Protein Incorporation into SARS-CoV-2 Pseudovirions.
     J Virol. 2023 Feb 15:e0165022. doi: 10.1128/jvi.01650.
     PubMed     Abstract available
     
     
     
267. WANG X, Wen Z, Cao H, Luo J, et al
     Transferrin Receptor Protein 1 Cooperates with mGluR2 To Mediate the Internalization of Rabies Virus and SARS-CoV-2.
     J Virol. 2023 Feb 13:e0161122. doi: 10.1128/jvi.01611.
     PubMed     Abstract available
     
     
     
268. WANG Y, Ge F, Wang J, Li H, et al
     Mycobacterium bovis BCG Given at Birth Followed by Inactivated Respiratory Syncytial Virus Vaccine Prevents Vaccine-Enhanced Disease by Promoting Trained Macrophages and Resident Memory T Cells.
     J Virol. 2023 Feb 13:e0176422. doi: 10.1128/jvi.01764.
     PubMed     Abstract available
     
     
     
269. AMANAT F, Clark J, Carreno JM, Strohmeier S, et al
     Immunity to Seasonal Coronavirus Spike Proteins Does Not Protect from SARS-CoV-2 Challenge in a Mouse Model but Has No Detrimental Effect on Protection Mediated by COVID-19 mRNA Vaccination.
     J Virol. 2023 Feb 13:e0166422. doi: 10.1128/jvi.01664.
     PubMed     Abstract available
     
     
     
270. BEI C, Zhang C, Wu H, Feng H, et al
     DDX3X Is Hijacked by Snakehead Vesiculovirus Phosphoprotein To Facilitate Virus Replication via Stabilization of the Phosphoprotein.
     J Virol. 2023 Feb 6:e0003523. doi: 10.1128/jvi.00035.
     PubMed     Abstract available
     
     
     
271. SCHINDEWOLF C, Lokugamage K, Vu MN, Johnson BA, et al
     SARS-CoV-2 Uses Nonstructural Protein 16 To Evade Restriction by IFIT1 and IFIT3.
     J Virol. 2023 Feb 1:e0153222. doi: 10.1128/jvi.01532.
     PubMed     Abstract available
     
     
     January 2023
272. GOODRUM F, Lowen A, Lakdawala S, Alwine J, et al
     Virology under the Microscope-a Call for Rational Discourse.
     J Virol. 2023 Jan 26:e0008923. doi: 10.1128/jvi.00089.
     PubMed     Abstract available
     
     
     
273. LIU MQ, Lin HF, Li J, Chen Y, et al
     A SARS-CoV-2-Related Virus from Malayan Pangolin Causes Lung Infection without Severe Disease in Human ACE2-Transgenic Mice.
     J Virol. 2023 Jan 23:e0171922. doi: 10.1128/jvi.01719.
     PubMed     Abstract available
     
     
     
274. RAJAGOPALA SV, Strickland BA, Pakala SB, Kimura KS, et al
     Mucosal Gene Expression in Response to SARS-CoV-2 Is Associated with Viral Load.
     J Virol. 2023 Jan 19:e0147822. doi: 10.1128/jvi.01478.
     PubMed     Abstract available
     
     
     
275. MA J, Liu X, Zhou M, Chen P, et al
     A Heterologous Challenge Rescues the Attenuated Immunogenicity of SARS-CoV-2 Omicron BA.1 Variant in Syrian Hamster Model.
     J Virol. 2023 Jan 18:e0168422. doi: 10.1128/jvi.01684.
     PubMed     Abstract available
     
     
     September 2021
276. TANG W, Li Y, Song Q, Wang Z, et al
     Mechanism of Cross-Resistance to Fusion Inhibitors Conferred by the K394R Mutation in Respiratory Syncytial Virus Fusion Protein.
     J Virol. 2021;95:e0120521.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Influenza is free of charge.